Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Cash from Financing Activities (2016 - 2025)

Apyx Medical (APYX) has disclosed Cash from Financing Activities for 15 consecutive years, with $9.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities rose 40.31% year-over-year to $9.5 million, compared with a TTM value of $9.6 million through Dec 2025, up 42.03%, and an annual FY2025 reading of $9.6 million, up 42.03% over the prior year.
  • Cash from Financing Activities was $9.5 million for Q4 2025 at Apyx Medical, up from $45000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $23.8 million in Q4 2023 and bottomed at -$61000.0 in Q1 2021.
  • Average Cash from Financing Activities over 5 years is $2.4 million, with a median of $35000.0 recorded in 2025.
  • The sharpest move saw Cash from Financing Activities plummeted 506.67% in 2021, then skyrocketed 238540.0% in 2023.
  • Year by year, Cash from Financing Activities stood at -$39000.0 in 2021, then surged by 74.36% to -$10000.0 in 2022, then surged by 238540.0% to $23.8 million in 2023, then crashed by 71.65% to $6.8 million in 2024, then surged by 40.31% to $9.5 million in 2025.
  • Business Quant data shows Cash from Financing Activities for APYX at $9.5 million in Q4 2025, $45000.0 in Q3 2025, and $25000.0 in Q2 2025.